Spika J S, Fedson D S, Facklam R R
Bureau of Communicable Disease Epidemiology, Laboratory Centre for Disease Control, Ottawa, Ontario, Canada.
Infect Dis Clin North Am. 1990 Mar;4(1):11-27.
The morbidity and mortality associated with pneumococcal infections are preventable in many high-risk individuals by immunization with 23-valent pneumococcal vaccine. While the clinical effectiveness of the current vaccine is less than ideal, use of the vaccine is cost effective. In spite of recommendations for pneumococcal vaccination of elderly and other high-risk persons, and federal reimbursement for vaccination Medicare enrollees, it was estimated in 1985 that only 10% to 15% of this target population was immunized. Strategies for immunizing high-risk individuals with pneumococcal vaccine need to involve physicians, public health professionals, health advocacy groups, and persons in the targeted populations.
对于许多高危个体而言，通过接种23价肺炎球菌疫苗可预防与肺炎球菌感染相关的发病率和死亡率。虽然目前疫苗的临床效果不尽理想，但使用该疫苗具有成本效益。尽管有针对老年人和其他高危人群接种肺炎球菌疫苗的建议，且联邦政府为医疗保险参保者的疫苗接种提供报销，但据1985年估计，该目标人群中只有10%至15%的人接种了疫苗。为高危个体接种肺炎球菌疫苗的策略需要医生、公共卫生专业人员、健康倡导团体以及目标人群中的个体共同参与。
